Cvs Pharmacy #02817 | |
1418 P St Nw, Washington, District Of Columbia 20005 | |
(202) 939-5735 |
Name | Cvs Pharmacy #02817 |
---|---|
Organization Name | District Of Columbia Cvs Pharmacy Llc |
Location | 1418 P St Nw, Washington, District Of Columbia 20005 |
Type | Durable Medical Equipment & Medical Supplies Supplier |
Phone | (202) 939-5735 |
Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Boston Scientific Corporation today announced that it has received U.S. Food and Drug Administration clearance for the two validated manufacturing changes affecting all of its cardiac resynchronization therapy defibrillators and implantable cardioverter defibrillators, and that it will immediately resume distribution of its COGNIS CRT-Ds and TELIGEN ICDs.
The patent which is assigned to the University of Pittsburgh has been exclusively licensed to PRP. The drug, known as PulmoLAR, containing 2ME as active ingredient, is currently developed by PRP for the treatment of pulmonary arterial hypertension (PAH).
4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the presentation of Phase II data from Hodgkin Lymphoma patients treated in the 1st Simon Stage cohort of the ongoing SAPHIRE study with resminostat (4SC-201), an oral pan-histone deacetylase (HDAC) inhibitor, at the 8th International Symposium on Hodgkin Lymphoma in Cologne, Germany.
Children around the world who grow up in dangerous neighborhoods exhibit more aggressive behavior, says a new Duke University-led study that is the first to examine the topic across a wide range of countries.
› Verified 3 days ago
NPI Number | 1295839264 |
Organization Name | DISTRICT OF COLUMBIA CVS PHARMACY, L.L.C. |
Doing Business As | CVS PHARMACY #02817 |
Type | Durable Medical Equipment & Medical Supplies Supplier |
Address | 1418 P St Nw, Washington, DC 20005 |
Phone Number | 202-939-5735 |
News Archive
Boston Scientific Corporation today announced that it has received U.S. Food and Drug Administration clearance for the two validated manufacturing changes affecting all of its cardiac resynchronization therapy defibrillators and implantable cardioverter defibrillators, and that it will immediately resume distribution of its COGNIS CRT-Ds and TELIGEN ICDs.
The patent which is assigned to the University of Pittsburgh has been exclusively licensed to PRP. The drug, known as PulmoLAR, containing 2ME as active ingredient, is currently developed by PRP for the treatment of pulmonary arterial hypertension (PAH).
4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the presentation of Phase II data from Hodgkin Lymphoma patients treated in the 1st Simon Stage cohort of the ongoing SAPHIRE study with resminostat (4SC-201), an oral pan-histone deacetylase (HDAC) inhibitor, at the 8th International Symposium on Hodgkin Lymphoma in Cologne, Germany.
Children around the world who grow up in dangerous neighborhoods exhibit more aggressive behavior, says a new Duke University-led study that is the first to examine the topic across a wide range of countries.
› Verified 3 days ago
News Archive
Boston Scientific Corporation today announced that it has received U.S. Food and Drug Administration clearance for the two validated manufacturing changes affecting all of its cardiac resynchronization therapy defibrillators and implantable cardioverter defibrillators, and that it will immediately resume distribution of its COGNIS CRT-Ds and TELIGEN ICDs.
The patent which is assigned to the University of Pittsburgh has been exclusively licensed to PRP. The drug, known as PulmoLAR, containing 2ME as active ingredient, is currently developed by PRP for the treatment of pulmonary arterial hypertension (PAH).
4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the presentation of Phase II data from Hodgkin Lymphoma patients treated in the 1st Simon Stage cohort of the ongoing SAPHIRE study with resminostat (4SC-201), an oral pan-histone deacetylase (HDAC) inhibitor, at the 8th International Symposium on Hodgkin Lymphoma in Cologne, Germany.
Children around the world who grow up in dangerous neighborhoods exhibit more aggressive behavior, says a new Duke University-led study that is the first to examine the topic across a wide range of countries.
› Verified 3 days ago
We Work Office Building Type: Durable Medical Equipment & Medical Supplies Supplier Location: 80 M St Se, Washington, District Of Columbia 20003 Phone: (844) 417-8633 | |
Medstar Pharmacy(store #5) Type: Community/Retail Pharmacy Location: 106 Irving St Nw, Washington, District Of Columbia 20010 Phone: (202) 877-6309 | |
Cvs Pharmacy 02733 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1601 17th St Nw, Washington, District Of Columbia 20009 Phone: (202) 588-0186 | |
New Hampshire Pharmacy & Medical Eq Type: Durable Medical Equipment & Medical Supplies Supplier Location: 5001 New Hampshire Ave Nw, Washington, District Of Columbia 20011 Phone: (202) 726-3100 | |
District Clinical Services Type: Durable Medical Equipment & Medical Supplies Supplier Location: 20 F St Nw, Washington, District Of Columbia 20001 Phone: (888) 342-2254 |